loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Anupam Rasayan India Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Anupam Rasayan India Ltd. 17 Oct 2025 11:39 AM
Result PDF

Q2FY26 Quarterly Result Announced for Anupam Rasayan India Ltd.

Specialty Chemicals company Anupam Rasayan India announced Q2FY26 results

  • Total revenue for Q2FY26 was at Rs 7,392 million as compared to Rs 2,959 million in Q2FY25; up 149% YoY.
  • EBITDA (incl. other income) was at Rs 1,436 million in Q2FY26 as compared to Rs 824 million in Q2FY25, up 74% and this would translate into 19% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 572 million in Q2FY26 as compared to Rs 306 million in Q2FY25; up 87% YoY.

Anand Desai, Managing Director, Anupam Rasayan, said, “I am delighted to share that Q2FY26 has been one of the best quarters for our company. We delivered a stellar performance with consolidated revenue from operations of Rs 739 crore, reflecting exceptional growth of 149% YoY and 51% sequentially. For H1FY26, consolidated revenue stood at Rs 1,229 crore, registering a robust 122% YoY growth.

I am pleased to highlight that within just six months of this financial year, we have already surpassed the total revenue of FY25, demonstrating the resilience of our business model, strong customer relationships, and operational excellence. Our subsidiary, Tanfac Industries, also delivered a strong performance during H1FY26, reporting revenue of Rs 345 crore, marking a 67% YoY growth.”

Result PDF

Result PDF

Specialty Chemicals company Anupam Rasayan India announced Q1FY26 results

  • Total revenue for Q1FY26 was at Rs 4,907 million as compared to Rs 2,603 million in Q1FY25; up 89% YoY.
  • EBITDA (incl. other income) was at Rs 1,292 million in Q1FY26 as compared to Rs 592 million in Q1FY25, up 118% and this would translate into 26% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 485 million in Q1FY26 as compared to Rs 122 million in Q1FY25; up 297% YoY.

Anand Desai, Managing Director, Anupam Rasayan, said: “During Q1FY26, consolidated revenue stood at Rs 491 crore, registering a robust growth of 89% year-on-year. We strongly believe that the sectoral trends are in our favour, and we are witnessing a clear resurgence in growth. Our pharma and polymer businesses are performing well, coupled with a recovery in the Agrochemical segment.

The USA and Japan markets have shown encouraging trends for Anupam Rasayan. During Q1FY26, total exports accounted for 58% of the total revenue from operations.

With the two new agreements signed with Japanese and US-based multinational companies, our order book now stands at Rs 14,646 crore, reflecting the strong growth momentum in our business.”

Result PDF

Specialty Chemicals company Anupam Rasayan India announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Total revenue for Q4FY25 was at Rs 5,057 million as compared to Rs 4,130 million in Q4FY24; up 22% YoY.
  • EBITDA (incl. other income) was at Rs 1,500 million in Q4FY25 as compared to Rs 1,047 million in Q4FY24, up 43% and this would translate into 30% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 629 million in Q4FY25 as compared to Rs 405 million in Q4FY24; up 56% YoY.

FY25 Financial Highlights:

  • Total revenue for FY25 was at Rs 14,485 million as compared to Rs 15,053 million in FY24; down 4% YoY.
  • EBITDA (incl. other income) was at Rs 4,123 million in FY25 as compared to Rs 4,109 million in FY24, this would translate into 28% EBITDA margin in FY25.
  • Profit After Tax was at Rs 1,600 million in FY25 as compared to Rs 1,674 million in FY24.

Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “Consolidated revenue for the quarter Q4FY25 stood at Rs 506 crores registering a growth of 22% YoY and 31% QoQ. Consolidated revenue for the full year FY25 stood at Rs 1,448 crores registering a degrowth of 4% YoY. This performance was supported by growth in pharma and polymer coupled with strong performance from Tanfac. Margins have remained consistent this quarter, reflecting our focus on operational efficiency and a favourable product mix.

While H1 FY25 was subdued due to weak macro conditions, I am pleased to share that H2 has shown clear signs of recovery — particularly in Q4 FY25 where we have seen meaningful improvement with sales increasing both year-on-year and sequentially. We remain confident in our ability to return to the historical growth rates achieved prior to the recent slowdown.”

Result PDF

Specialty Chemicals company Anupam Rasayan India announced Q3FY25 results

  • Total revenue for Q3FY25 was at Rs 3,866 million as compared to Rs 2,979 million in Q3FY24; up 30% YoY.
  • EBITDA (incl. other income) was at Rs 1,208 million in Q3FY25 as compared to Rs 815 million in Q3FY24, up 48% and this would translate into 31% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 542 million in Q3FY25 as compared to Rs 260 million in Q3FY24; up 108% YoY.

Anand Desai, Managing Director, Anupam Rasayan commented, “Our Pharma and Polymer segments, which have emerged as key growth drivers, continue to strengthen their contribution to our revenue. Both the segments coupled with strong performance of Tanfac led to significant growth this quarter, fueling a robust 31% QoQ revenue growth in Q3FY25 on a consolidated basis. For the full year, we expect them to play a substantial role in overall revenue, with this upward trend projected to continue into FY26. Additionally, the Agrochemical segment has shown signs of recovery, particularly in the European market."

"With strong demand momentum and expected off-take from our customers, we anticipate regaining our growth trajectory in the next financial year, aiming for a 30-35% revenue increase in FY26.

Result PDF

Specialty Chemicals company Anupam Rasayan India announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Total revenue for Q2FY25 was at Rs 2,959 million as compared to Rs 3,956 million in Q2FY24.
  • EBITDA (incl. other income) was at Rs 824 million in Q2FY25 as compared to Rs 1,109 million in Q2FY24, this would translate into 28% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 306 million in Q2FY25 as compared to Rs 487 million in Q2FY24.

H1FY25 Financial Highlights:

  • Total revenue for H1FY25 was at Rs 5,562 million as compared to Rs 7,944 million in H1FY24.
  • EBITDA (incl. other income) was at Rs 1,416 million in H1FY25 as compared to Rs 2,247 million in H1FY24, this would translate into 25% EBITDA margin in H1FY25.
  • Profit After Tax was at Rs 428 million in H1FY25 as compared to Rs 1,009 million in H1FY24.

Anand Desai, Managing Director, Anupam Rasayan said: "In Q2FY25, we were nearing the end of a demand slump in the Agro segment, and we are now seeing a good recovery. The Pharma and Polymer segments, meanwhile, have been showing robust growth, fuelled by the launch of over 17 new molecules in FY24 and 3 additional molecules in H1FY25. As these products gain traction, we expect their contribution to grow. Additionally, the planned launch of more than 3 new molecules in the coming months should further accelerate growth in these areas.

Our consolidated operating revenue for the quarter was Rs 294 crores, representing a QoQ growth of 14%, with a stable EBITDA margin of 28% in Q2FY25. We anticipate revenue to normalize as volumes increase in the latter half of the year. With the new capacity, scaling of recently launched fluorinated molecules, and signed LOIs and contracts, we are optimistic about strong growth over the medium term."

Result PDF

Speciality Chemicals company Anupam Rasayan India announced consolidated Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Total revenue for Q4FY24 was at Rs 4,130 million as compared to Rs 5,042 million in Q4FY23; down 18% YoY.
  • EBITDA (incl. other income) was at Rs 1,047 million in Q4FY24 as compared to Rs 1,416 million in Q4FY23 – degrowth of 26% YoY, this would translate into 25% EBITDA margin in this quarter.
  • Profit After Tax was at Rs 405 million in Q4FY24 as compared to Rs 726 million in Q4FY23 - degrowth of 44% YoY. 

FY24 Financial Highlights:

  • Total revenue for FY24 was at Rs 15,053 million as compared to Rs 16,105 million in FY23; down 7% YoY.
  • EBITDA (incl. other income) was at Rs 4,109 million as compared to Rs 4,399 million in FY23 – degrowth of 7.0% YoY, this would translate into 27% EBITDA margin.
  • Profit After Tax was at Rs 1,674 million as compared to Rs 2,168 million in FY23 - degrowth of 23% YoY. 

Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “Indian chemical industry including spec chem industry has faced significant headwinds during the last year. However, despite the de-growth in the top-line, we have been able to sustain our profitability and maintain margins at 27% levels on a full year consolidated basis. During the year, the Agro chemical industry in particular faced challenges, however our past sustained efforts in expanding our pharma and polymer portfolio have started yielding results leading to pharma contributing over 9% of revenue in FY24, up from 4% last year. We expect pharma and polymer segment each to further increase their revenue share in double digits by next year.

In FY2024, we have focused on expanding our customers, products and end market applications. We have added 17 new molecules, 4 new MNCs including 2 Japanese majors and expanded contribution from polymer and pharma which going forward will lead to balanced product portfolio from end market perspective.

We believe that headwinds in the industry may continue for the next two quarters. However, financial year 2025 will be a year of growth for us with our major focus on polymer and pharmaceutical space.”

Result PDF

Agrochemicals company Anupam Rasayan announced consolidated 9MFY24 results:

  • Total revenue for 9MFY24 was at Rs 10,923 million compared to Rs 11,062 million in 9MFY23, representing a decrease of 1.26% YoY.
  • EBITDA (including other income) was at Rs 3,062 million in 9MFY24 compared to Rs 2,984 million in 9MFY23, reflecting a growth of 2.62% YoY. This translates into a 28.03% EBITDA margin.
  • Profit After Tax was at Rs 1,270 million in 9MFY24 compared to Rs 1,442 million in 9MFY23.

Commenting on the performance, Anand Desai, Managing Director of Anupam Rasayan, remarked, “The chemical industry continues to face headwinds impacting our performance for the quarter. This, coupled with clients off-taking minimum required quantities to manage their year-end working capital, has led to a degrowth in our revenues for the quarter. Even during such difficult times, we have been able to maintain our margins steady at 28% for the 9MFY24 on a consolidated basis.

I am happy to inform you that, during the quarter, we signed a Letter of Intent worth $61 million i.e., Rs 507 crore for the next 9 years with one of the leading Japanese Chemical companies to supply new age polymer intermediate. I firmly believe that our Japan business will see strong growth in the coming years and will likely become a major business centre for Anupam.

As a next step forward in our sustainability journey, the company has decided to invest Rs 59 crore towards setting up a 9.6 MW hybrid (Wind plus Solar) power plant. Post completion of this capex, 65% of the company’s electricity consumption will be from green energy.

Overall, I believe FY24 will be a challenging year for the industry but with a resilient and robust business model like ours, I am confident that FY25 will be a year of demand resurgence and strong growth.”

 

Result PDF

Agrochemicals company Anupam Rasayan announced Q1FY24 results:

  • Total Revenue at Rs 3,988 million in Q1FY24 as compared to Rs 3,343 million in Q1FY23 – growth of 19% YoY.
  • EBITDA (incl. other revenue) at Rs 1,138 million in Q1FY24 as compared to Rs 892 million in Q1FY23 – growth of 28% YoY.
  • Profit After Tax at Rs 523 million in Q1FY24 as compared to Rs 420 million in Q1FY23 - growth of 25% YoY

Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “I am delighted at the consistent growth momentum of the Company against a challenging industry backdrop. Our consolidated revenue witnessed a robust 19% YoY growth at Rs 3,988 million. While the falling prices of commodity agrochemicals are putting pressure on margins for the industry, our customised products and robust business model helped us deliver strong EBITDA margins of 29% in Q1FY24.

During the quarter, Anupam Rasayan signed an MoU with 3xper Innoventure Ltd., for the supply of targeted and identified new-age pharma molecules using a continuous process. The Company has also signed Letters of Intent (LOIs) worth Rs 40,660 million with Japanese and American MNCs for niche life sciences and specialty chemical molecules. These LOIs reinforce the growing confidence of global MNCs in our technical capabilities and think of us as the trusted partner of choice for high-end customised molecules. These LOIs improves our revenue visibility in the coming years.

Our order book remains strong despite a challenging external environment, giving us the confidence to deliver robust growth in FY24 while maintaining margins.”

 

Result PDF

Agrochemicals company Anupam Rasayan announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Operating Revenues at Rs 4,800 million in Q4FY23 as compared to Rs 3,249 million in Q4FY22 – growth of 48% YoY
    • Total Revenues at Rs 5,042 million in Q4FY23 as compared to Rs 3,169 million in Q4FY22 – growth of 59% YoY
    • EBITDA (incl. other revenue) at Rs 1,416 million in Q4FY23 as compared to Rs 969 million in Q4FY22 – growth of 46% YoY
    • Profit After Tax at Rs 726 million in Q4FY23 as compared to Rs 461 million in Q4FY22 - growth of 58% YoY
  • FY23:
    • Operating Revenues at Rs 16,019 million in FY23 as compared to Rs 10,738 million in FY22 – growth of 49% YoY
    • Total Revenues at Rs 16,105 million in FY23 as compared to Rs 10,811 million in FY22 – growth of 49% YoY
    • EBITDA (incl. other revenue) at Rs 4,399 million in FY23 as compared to Rs 3,121 million in FY22 – growth of 41% YoY
    • Profit After Tax at Rs 2,168 million in FY23 as compared to Rs 1,522 million in FY22 - growth of 42% YoY

Speaking on the performance, Anand Desai, Managing Director, Anupan Rasayan commented, "It gives me pleasure to share that we have continued our growth momentum with a 49% YoY revenue growth on the back of new products commercialized during the year as well as steady growth of the organic portfolio.

On the operations part, we continue to focus on adding more value-added products in our basket as well as bringing financial efficiencies. We have already started witnessing the results of the same which is visible in stable margins and improved working capital resulting in strong cash generation of Rs 2,440 million from operations.

Our strategic investments in infrastructure, people and technology have also started yielding great results which is visible in the growth that we have delivered as well as the new LOIs we have signed where majority of the customers are new clients. We will not stop here and further invest in strengthening and expanding these pillars of growth.

As we stand, we have signed contracts and LOIs of Rs 54,830 million giving us a strong revenue visibility for the coming years. At the same time, we are witnessing a robust traction in customer engagement as we remain in advance stage of discussions with customers across geographies for many niche and high value molecules. All these factors give us a reassurance of sustained robust growth in FY24.”

 

 

Result PDF

Agrochemicals firm Anupam Rasayan Indian announced Q3FY23 results:

  • Q3FY23:
    • Operating revenues at Rs 3,827 million in Q3FY23 as compared to Rs 2,662 million in Q3FY22 – growth of 44% YoY.
    • Total revenues at Rs 3,888 million in Q3FY23 as compared to Rs 2,711 million in Q3FY22 – growth of 43% YoY.
    • EBITDA (incl. other revenue) at Rs 1,080 million in Q3FY23 as compared to Rs 800 million in Q3FY22 – growth of 35% YoY.
    • Profit After Tax at Rs 544 million in Q3FY23 as compared to Rs 379 million in Q3FY22 - growth of 44% YoY.

Anand Desai, Managing Director of Anupam Rasayan, commented, “I am pleased to inform you that despite unavailability of the certain capacities during the quarter, we were able to deliver growth on YoY basis. If you adjust the deferred revenue due to capacity constrain then our growth would have been around 25% during the quarter.

I am delighted to share that we have received approval to restart the plant from the GPCB and other regulatory authorities after following all the regulatory and safety compliances. This shows our unwavering focus on compliance and maintaining high levels of manufacturing and safety standards, which has helped us get the closure order lifted within a shorter time span.

We continue to strengthen our business development team as we have a strong pipeline of products to launch in coming quarters. Our customer interactions remain very encouraging, and we have specifically seen strong interest from various customers on the fluorination side.

Overall, our strong pipeline of products, availability of the capacity, advance stage discussion with various clients along with capex which is moving ahead of the plan makes me confident of delivering strong and sustainable growth in coming quarters and years.”

Result PDF

Trending News

Silver price hits new high

As per media sources, silver prices reached an all-time high of $67 per ounce for the first time yesterday.

Published on 22-Dec-2025 09:13

Krishna Institute sets up super speciality hospital

Krishna Institute of Medical Sciences Limited has entered into a lease and licence agreement with Andhra Mahila Sabha to lease around 1.168 acres of land in Chennai for setting up a super speciality hospital. 

Published on 22-Dec-2025 09:12

Delhi cracks down on liquor cartels

According to media reports, Delhi government is cracking down on liquor cartels even as the top selling liquor brands remain the same in the national capital as during the previous Aam Aadmi Party (AAP) regime. 

Published on 22-Dec-2025 09:11

Titan aims for $1 billion watch sales

Titan is optimistic for its watch business, which is expected to touch the $1 billion sales mark in the next two years, led by factors such as premiumisation, retail footprint expansion and growth of the international business division. 

Published on 22-Dec-2025 09:10

Shree Cement gets greenlight for ₹2,000 cr cement plant

As per media reports, Shree Cement has signed an LoI with Maharashtra to set up a 2 mtpa cement plant in Chandrapur district, Maharashtra with an investment of Rs 2000 crore. 

Published on 22-Dec-2025 09:09

US President signs national defense act

The US President has signed the National Defense Authorisation Act, an amended version of the US Biosecure Act. 

Published on 22-Dec-2025 09:08

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status